Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Trial Profile

Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs UCART 123 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Acronyms ABC123
  • Sponsors Cellectis
  • Most Recent Events

    • 28 Jun 2017 Status changed from planning to recruiting.
    • 06 Mar 2017 According to a Cellectis media release, this trial will be led at the MD Anderson Cancer Center, by Dr. Naveen Pemmaraju, MD, Assistant Professor and Hagop Kantarjian, MD., Professor and Department Chair, Department of Leukemia, Devision of Cancer Medicine.
    • 06 Feb 2017 According to a Cellectis media release, company received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top